Press Releases Spero Therapeutics, Inc.

Equities

SPRO

US84833T1034

Real-time Estimate Cboe BZX Other stock markets 11:40:46 2024-05-06 am EDT			5-day change	1st Jan Change
1.655 ^USD	+1.53%		+15.28%	+12.93%

Mar. 13	Transcript : Spero Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024
Mar. 13	Spero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	May. 01	AQ
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update	Mar. 13	AQ
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024	Mar. 06	AQ
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections	Feb. 28	AQ
Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference	Feb. 26	AQ
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Jan. 31	AQ
Spero Therapeutics Provides Corporate Update and 2024 Outlook	Jan. 05	AQ
Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections	Jan. 02	AQ
Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update	Nov. 13	AQ
Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023	Nov. 06	AQ
SPERO ALERT: Bragar Eagel & Squire, P.C. is Investigating Spero Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm	Nov. 02	BU
Spero Therapeutics to Present at Upcoming November Investor Conferences	Nov. 01	AQ
Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer	Nov. 01	AQ
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	23-10-31	AQ
Purcell & Lefkowitz LLP Is Investigating Spero Therapeutics, Inc. (NASDAQ: SPRO) for Potential Breaches of Fiduciary Duty By Its Board of Directors	23-10-11	PR
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	23-09-29	AQ
Spero Therapeutics to Present at Cantor’s Global Healthcare 2023 Investor Conference	23-09-20	AQ
Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference	23-09-06	AQ
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	23-08-31	AQ
Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business Update	23-08-10	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Spero Therapeutics, Inc.

Equities

SPRO

US84833T1034

Press Releases

Filters